The Vaccine Company Investors Keep Underestimating

A lot of biotech stocks get labeled by their last blockbuster. This one is trying to flip the script with a high-stakes oncology catalyst that could turn a faded pandemic narrative into a real platform story again.

If the next data and timelines hold up, the move higher does not need hype, it just needs credibility.

Open Door (Sponsored)

You Don’t Need to Be an Insider This Time

A major tech company is preparing for what could become the largest IPO in history—and early investors are already positioning themselves for what’s next.

According to new research, a breakthrough project could soon connect billions of devices worldwide through ultra-fast satellite technology—unlocking an opportunity valued at over $2 trillion.

And here’s the surprising part: you don’t need insider access or accredited status to get involved.

You can take part using a regular brokerage account for less than $100.

[Click Here to See the Full Story]

*This ad is sent on behalf of Paradigm Press, LLC, at 1001 Cathedral St., Baltimore, MD 21201. If you're not interested in this opportunity from Paradigm Press, LLC, please click here to remove your email from these offers.

Never Miss a Stock Alert Again!

We now send our daily picks via SMS too — so you’ll get the same high-conviction ideas, even if you miss the email.

👉 Click here to get stock picks by text and stay in the loop, always.

Live Nation Entertainment | LYV

Price: $147.80

Live Nation is still the toll booth on live entertainment, but the stock trades like investors are constantly re-litigating the same debate: incredible demand, messy optics.

Shares are only modestly higher over the last year, even as concerts remain one of the last big consumer splurges people defend in a tight budget environment.

The business is structurally strong, but it is never far from regulatory noise, pricing backlash, and margin scrutiny.

The upside case is straightforward. If 2026 keeps rewarding experiences over stuff, Live Nation benefits from pricing power, sponsorship dollars, and the flywheel of tours and festivals.

Partnerships can help expand the monetization layer around events and improve the fan experience without needing infinite ticket price hikes. 

Why it matters for you: LYV is a demand story with headline risk. If you want exposure, size it like a durable winner that can still get hit on sentiment.

Fortinet | FTNT

Price: $83.07

Fortinet is a reminder that even strong cybersecurity platforms can have dead periods. The stock has been soft over the past year, which usually signals the market is questioning billings momentum, competitive intensity, or the durability of firewall refresh cycles.

But security budgets do not disappear, they get reprioritized. When fear rises, companies often spend on prevention before they spend on new projects.

The setup for Fortinet is about re-acceleration and credibility. If management shows stabilization in demand, cleaner guidance, and improving platform mix, the stock can regain respect quickly.

The risk is that cyber is crowded, and the market will punish any sign that growth is drifting toward being merely decent instead of dominant.

Why it matters for you: FTNT is not broken, but it needs a proof quarter. Watch results and guidance closely because that is what flips sentiment.

Top Tier (Sponsored)

A Rare Screen Just Flagged These 5 Stocks

From thousands of stocks, only five stood out as having the best chance to gain +100% or more in the months ahead.

A newly released 5 Stocks Set to Double special report reveals all five tickers — free for a limited time.

While future results can’t be guaranteed, previous editions of this report delivered gains of +175%, +498%, and even +673%.

The newest picks could follow a similar path.

This free opportunity expires at MIDNIGHT TONIGHT.

Get the free report here

*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.

Smurfit WestRock | SW

Price: $43.38

Packaging is rarely exciting, which is exactly why it can work when markets get jumpy.

Smurfit WestRock has been weak over the last year, but the company sits in the kind of essential category that quietly benefits when supply chains normalize and industrial demand steadies.

You are not buying a hype story here. You are buying scale, staples-like demand, and the potential for integration wins.

This name is about execution: capturing synergies, managing pricing in a cyclical end market, and protecting cash flow when volumes wobble.

The dividend adds a real return component, which matters more when investors start caring about durability again. 

Why it matters for you: SW is a steadier profile than most cyclicals. If 2026 gets choppier, boring cash flow can outperform.

Intel | INTC

Price: $42.49

Intel has been one of the most emotional stocks in the market, and the recent swing shows why. Investors want to believe in an AI infrastructure comeback, but they also demand real delivery.

The key tension is capacity and yields. When demand is real but supply is constrained, the market does not reward the story, it punishes the shortfall.

What makes Intel interesting now is not hype about AI, it is whether the company can translate demand into shipments with acceptable margins.

If supply tightness eases on schedule and manufacturing execution improves, the rerate can continue. If timelines slip, volatility stays high because expectations reset fast.

Recent reports highlighted supply constraints and execution bottlenecks as near-term focus points.

Why it matters for you: INTC can move hard in both directions. Treat it like a catalyst-driven turnaround, not a set-and-forget compounder.

Moderna | MRNA

Price: $47.99

This is the stock the title is really about. Moderna is still fighting the market’s instinct to label it as a one-era winner.

The bull case is that the platform is real and oncology is the bridge to a durable second act.

Recent long-term data tied to its personalized cancer vaccine work with Merck helped bring that debate back to the front of the market’s mind. 

The opportunity is narrative plus timeline.

If investors get a credible Phase 3 path, clearer visibility into commercialization, and signs the company can manage cash burn while building the pipeline, sentiment can shift from skepticism to respect.

The bear case is also simple: Phase 3 is unforgiving, timelines stretch, and biotech rerates can fade fast without fresh proof.

Why it matters for you: MRNA is a pipeline credibility trade. If oncology momentum holds, the stock can rerate without needing the market to care about COVID ever again.

Stat of the Day: $5,000

Gold ripped past $5,000 an ounce over the weekend, another sign that investors are paying up for protection as geopolitical risks stack up and confidence in smooth outcomes stays fragile.

Even if you do not trade commodities, the signal matters: when gold acts like this, markets are usually prioritizing resilience over perfection.